The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

NCT01181986 on ClinicalTrials.gov · last registry update 2014-05-20

Finished December 2012, after enrolling 76 people. Primary outcome, as filed: Reactive Hyperemia Index (RHI). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Carl T. Hayden VA Medical Center
Sponsor type: Fed
Enrollment: 76
Started: 2010-08
Primary completion: 2012-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Reactive Hyperemia Index (RHI)

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.